|Catalog||Size (Price)||Quantity||In Stock||Operation||Other Information|
SEMA4D / CD100 Antibody Datasheet
|Order or Inquire for SEMA4D / CD100 Antibody product||Quality antibodies||Antibody production services|
|Detection limit is 0.039 ng/well in ELISA|
SEMA4D / CD100 Antibody Product Information
Recombinant Human SEMA4D / CD100 protein (Catalog#11825-H08H)
|Antibody Type :||Mouse Monoclonal Antibody ( Mouse mAb Service Platform )|
Clone ID :
|Ig Type :||
|Formulation :||0.2 μm filtered solution in PBS with 5% trehalose|
This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human SEMA4D / CD100 (rh SEMA4D / CD100; Catalog#11825-H08H; Q92854-1; Met 1-Arg 734). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.
SEMA4D / CD100 Antibody Usage Guide
Human SEMA4D / CD100
No cross-reactivity in ELISA with
Human cell lysate (293 cell line)
|Direct ELISA :||This antibody can be used at 0.5-1 μg/mL with the appropriate secondary reagents to detect Human SEMA4D. The detection limit for Human SEMA4D is approximately 0.039 ng/well.|
|Storage :||This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
SEMA4D / CD100 Antibody Related Products & Topics
|Molecule||Species||Description //For Detailed Info. and Price------CLICK!||Cat. No|
|Syndecan-1/SDC1/CD138||Human||Syndecan-1/SDC1/CD138 Protein, Recombinant||11429-H08H|
|Syndecan-1/SDC1/CD138||Mouse||Syndecan-1/SDC1/CD138 Protein, Recombinant||50641-M08H|
|Syndecan-1/SDC1||Rat||SDC1 / Syndecan-1 / SYND1 Protein, Recombinant||80344-R02H|
|Syndecan-1/SDC1||Rat||SDC1 / Syndecan-1 / SYND1 Protein, Recombinant||80344-R08H|
|Molecule||Application||Description //For Detailed Info. and Price------CLICK!||Cat. No|
|Human Semaphorin 4D/SEMA4D/CD100||WB, ELISA||SEMA4D / CD100 Antibody||11825-MM02|
|Human Semaphorin 4D/SEMA4D/CD100||ELISA||SEMA4D / CD100 Antibody||11825-MM06|
|Human Semaphorin 4D/SEMA4D/CD100||WB, ELISA||SEMA4D / CD100 Antibody||11825-RP01|
|Human Semaphorin 4D/SEMA4D/CD100||WB, ELISA||SEMA4D / CD100 Antibody (Antigen Affinity Purified)||11825-RP02|
|Mouse Semaphorin 4D/SEMA4D/CD100||WB, ELISA||Semaphorin 4D / SEMA4D / CD100 Antibody||50642-RP01|
|Mouse Semaphorin 4D/SEMA4D/CD100||WB, ELISA||Semaphorin 4D / SEMA4D / CD100 Antibody (Antigen Affinity Purified)||50642-RP02|
SEMA4D / CD100 Antibody Background
Semaphorin-4D, also known as SEMA4D and CD100, is a single-pass type I membrane protein which belongs to thesemaphorin family. Semaphorin-4D / SEMA4D contains oneIg-like C2-type (immunoglobulin-like) domain, onePSI domain and oneSema domain. Semaphorin-4D / SEMA4D is strongly expressed in skeletal muscle, peripheral blood lymphocytes, spleen, and thymus and also expressed at lower levels in testes, brain, kidney, small intestine, prostate, heart, placenta, lung and pancreas, but not in colon and liver. Semaphorin-4D / SEMA4D may play a functional role in the immune system, as well as in the nervous system. Induces B-cells to aggregate and improves their viability. Semaphorin-4D / SEMA4D is an axon guidance molecule which is secreted by oligodendrocytes and induces growth cone collapse in the central nervous system. By binding plexin-B1 receptor it functions as an R-Ras GTPase-activating protein (GAP) and repels axon growth cones in both the mature central nervous system. In the immune system, Semaphorin-4D / SEMA4D binds CD72 to activate B cells and dendritic cells. It is involved in oligodendrogenesis during development and during recovery from ischemic injury.
- Masuda,K. et al., 2004, Genes Cells. 9 (9): 821-9.
- Duran-Struuck,R. et al., 2007,Biol Blood Marrow Transplant 13 (11): 1294 -1303.
- Taniguchi,Y. et al., 2009,J Neurosci Res. 87 (13): 2833-41.
- Ch'ng,E.S. et al., 2010, Mol Cancer. 9: 251.